title: Blood pressure effects of naproxcinod in hypertensive patients.
abstract: The blood pressure (BP) effects of naproxcinod and naproxen were assessed in an 8-week, double-blind, crossover study in 131 hypertensive patients aged 50 to 74 years. Patients received naproxcinod 750 mg twice daily or naproxen 500 mg twice daily, then the alternate treatment, each for 14 days, with placebo run-in/washout before each active treatment period and 24-hour ambulatory BP monitoring conducted before and after each active treatment period. Mean change from baseline in average 24-hour systolic BP (SBP) after 2 weeks of treatment numerically favored naproxcinod 750 mg twice daily (least-squares [LS] mean for naproxcinod minus naproxen: -1.6 mm Hg; P=.12). Post hoc analyses showed statistically significant SBP differences favoring naproxcinod for the 8 elapsed hours (LS mean: -4.4 mm Hg; P<.0001) and the 24 hours following morning dosing (LS mean: -2.4 mm Hg; P=.006). Naproxcinod may be a beneficial alternative for patients with osteoarthritis requiring nonsteroidal anti-inflammatory drugs.
authors.affiliation: Hospital of theUniversity of Pennsylvania, 3400 Spruce Street,Philadelphia, PA 19104, USA. townsend@mail.med.upenn.edu
authors.forename: Raymond
authors.initials: R
authors.lastname: Townsend
authors.forename: Neville
authors.initials: N
authors.lastname: Bittar
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Rosen
authors.forename: William
authors.initials: W
authors.lastname: Smith
authors.forename: Andrea
authors.initials: A
authors.lastname: Ramsay
authors.forename: Steven G
authors.initials: SG
authors.lastname: Chrysant
authors.forename: Robert
authors.initials: R
authors.lastname: Weiss
authors.forename: Aldina
authors.initials: A
authors.lastname: Pivodic
authors.forename: Brigitte
authors.initials: B
authors.lastname: Duquesroix
authors.forename: Jacques
authors.initials: J
authors.lastname: Djian
mesh_terms: D000368:Aged; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D018592:Cross-Over Studies; D016861:Cyclooxygenase Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D020030:Nitric Oxide Donors / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D016861:Cyclooxygenase Inhibitors; D020030:Nitric Oxide Donors; C111751:naproxen-n-butyl nitrate; D009288:Naproxen